Optimizerx Stock News

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx (NASDAQ:OPRX) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $0.04 (-75.0% Y/Y) and the…

This is OptimizeRxs largest enterprise-scale therapy initiation program launch to date This is OptimizeRxs largest enterprise-scale therapy initiation program launch to date

ROCHESTER, Mich., Feb. 22, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the "Company") (NASDAQ: OPRX ), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the launch of a large-scale therapy initiation program for a new anti-inflammatory biologic brand from a top 10 pharmaceutical company. The program is a key part of the manufacturer''s strategy to address patient therapy initiation challenges for its specialty drug launch, and it is OptimizeRx''s most expansive enterprise program to date. The deployment of OptimizeRx''s digital market access solution accelerates patient access to a new specialty drug which can reduce inflammation for a chronic condition and significantly improve the quality of life for this previously underserved patient population. The program streamlines therapy initiation for patients by ensuring that physicians have immediate electronic access to the appropriate enrollment forms needed to prescribe the medication.

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx (OPRX) announces preliminary Q4 revenue of $20.3M, resulting in a Y/Y growth of 42%.Improved gross margins and continued cost management are expected to result in a GAAP…

ROCHESTER, Mich., Feb. 01, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the "Company") (NASDAQ: OPRX ), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its vice president of data product, Mike Rousselle, has been named to MM+M''s 40 Under 40 List for his accomplishments and contributions to the healthcare marketing industry. In its third year, the 40 Under 40 list shines a light on the young marketers whose leadership, strategic thinking and digital facility have contributed to the industry''s continued growth at a challenging time for the healthcare business as a whole. The list includes individuals who hail from a range of employers, from pharma and biotech companies and agencies to device manufacturers, analytics firms and health media. At those organizations, the honorees hold a range of essential account, strategy and creative positions. With the world of medical marketing continuing to evolve in the digital era, these individuals inspire confidence that the industry is in good hands for the years ahead.

Here's why our roundtable participants like NRx Pharmaceuticals, FIGS, and OptimizeRx.

ROCHESTER, Mich., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the "Company") (NASDAQ: OPRX ), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced it has been named a winner in the 2022 BIG Innovation Awards presented by the Business Intelligence Group. The Business Intelligence Group''s annual BIG Innovation Awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways. OptimizeRx''s AI-Driven Therapy Initiation and Persistence platform empowers pharmaceutical manufacturers to easily implement and measure tech-enabled awareness, market access, and adherence programs. "Innovation is driving growth in the global economy," said Maria Jimenez, chief operating officer of the Business Intelligence Group. "We are thrilled to be honoring OptimizeRx''s AI-Driven Therapy Initiation and Persistence platform as they are one of the organizations leading this charge and helping humanity progress." Steve Silvestro, chief commercial officer at OptimizeRx said, "We are delighted to be recognized for our cutting-edge contribution to improving the lives and care of patients.

OptimizeRx Co. (NASDAQ:OPRX) insider Stephen L. Silvestro sold 13,241 shares of the companys stock in a transaction dated Friday, December 17th. The stock was sold at an average price of $54.87, for a total transaction of $726,533.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed [] The post OptimizeRx Co. (NASDAQ:OPRX) Insider Sells $726,533.67 in Stock appeared first on ETF Daily News .

ROCHESTER, Mich., Dec. 22, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the Company) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today issued an open letter from the CEO to shareholders detailing the completion of internal management changes. The full letter is published below:

Capita (OTCMKTS:CTAGY) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility and Risk Capita has a beta of 1.02, meaning that its stock price is 2% []

OptimizeRx Co. (NASDAQ:OPRX)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $55.43, but opened at $53.87. OptimizeRx shares last traded at $54.97, with a volume of 7 shares trading hands. A number of research analysts have issued reports on OPRX shares. Royal Bank of Canada upped their […]

OptimizeRx Co. (NASDAQ:OPRX) has been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered […]

Invesco Ltd. lifted its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 24.2% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,350 shares of the companys stock after buying an additional 1,824 shares during the period. Invesco Ltd. owned approximately 0.05% of OptimizeRx worth $579,000 []